Abstract 103P
Background
Texture analysis is used to assess the homogeneous or nonhomogenous information of the selected regions, and provides many quantitative and semiquantitative parameters that are able to closely reflect the characteristics of cancer lesions. This study was designed to estimate the clinical significance of the contrast-enhanced computed tomograpgy (CT) textural features for prediction of survival in colorectal cancer (CRC) patients receiving targeted therapy (bevacizumab and cetuximab).
Methods
The LifeX software was used to extract the textural parameters of the tumor lesions in the contrast-enhanced CT. Univariate and multivariate analyses using the Cox proportional hazards model were performed to assess the prognostic value of textural parameters.
Results
Eighty CRC patients receiving targeted therapy (bevacizumab 42; cetuximab 38) were included. In the multivariate analysis, 8 textural parameters were revealed to be independent predictors (p < 0.05) of progression-free survival (PFS) and overall survival (OS), including Skewness, Kurtosis, Homogeneity, Energy and Entropy of Gray-level co-occurrence matrix (GLCM), Long-run emphasis (LRE), Long-run high gray-level emphasis (LRHGE), and Contrast. Furthermore, Sphericity, Compacity, Long-run low gray-level emphasis (LRLGE), Low gray-level zone emphasis (LGZE) and Short-zone low gray-level emphasis (SZLGE) were show to be significantly associated with PFS, while Entropy-Histogram and Energy-Histogram, Dissimilarty, Short-run emphasis (SRE), Short-run low gray-level emphasis (SRLGE), Run percentage (RP), Long-zone emphasis (LZE), Long-zone low gray-level emphasis (LZLGE) and Long-zone high gray-level emphasis (LZHGE) were significantly associated with OS.
Conclusions
In conclusion, our study provides preliminary evidences that several radiomic parameters of tumor lesions derived from CT images were prognostic factors and predictive markers for CRC patients who are candidates for targeted therapy (bevacizumab and cetuximab).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
259P - The BOT patients fail to benefit from surgical staging procedures in prognosis and fertility outcomes: A retrospective analysis
Presenter: Li Na
Session: Poster display session
Resources:
Abstract
260P - Malignant ovarian germ cell tumours (MOGCT): Treatment results of 149 pts
Presenter: Dzhennet Chekini
Session: Poster display session
Resources:
Abstract
261P - Ovarian germ cell tumours - challenges and outcomes from a tertiary care centre in South India
Presenter: Vishnu Sreedath
Session: Poster display session
Resources:
Abstract
262P - Gestational trophoblastic tumours: Experience of the medical oncology department Hassan II University Hospital-Morocco about 29 cases
Presenter: Karima Oualla
Session: Poster display session
Resources:
Abstract
263TiP - ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled phase III study of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
264TiP - ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
265TiP - KEYNOTE-826: A phase III randomized study of chemotherapy with or without pembrolizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
271P - Comparison between CHOP like regimens and DAEPOCH with or without Rituximab in adult high grade B cell lymphoma NOS; A retrospective study from a tertiary cancer hospital in South India
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
272P - Melatonin increases the chemosensitivity of diffuse large Bell lymphoma cells to Epirubicin by inhibiting P-glycoprotein expression via the NF-κB pathway
Presenter: Xiuhua Sun
Session: Poster display session
Resources:
Abstract
273P - MALT1- A20 and NF-κB expression pattern in patients with non-Hodgkin lymphomas
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract